Etanercept therapy allows the tapering of methotrexate and sustained clinical responses in patients with moderate to severe psoriasis

In this: publication
By this: publisher
In this Subject: Dermatology
By this author: Yamauchi, Paul S. ;&nbsp; Lowe, Nicholas J.

Authors: Yamauchi, Paul S.; Lowe, Nicholas J.

Source: International Journal of Dermatology, Volume 47, Number 2, February 2008 , pp. 202-204(3)

Buy & download fulltext article:

Price: $48.00 plus tax (Refund Policy)

Abstract:

Methotrexate, the most common systemic small molecule used in the treatment of moderate to severe psoriasis, is associated with significant toxicities and adverse events. Long-term continuous usage is not recommended due to potential liver toxicity, myelosuppression, and other side effects. Abrupt cessation of methotrexate without tapering can lead to flare-up and rebound of psoriasis. Here we describe sustained clinical responses in 6 patients with psoriasis following gradual cessation of methotrexate through the addition of etanercept therapy.

Document Type: Research article

DOI: http://dx.doi.org/10.1111/j.1365-4632.2008.03419.x

Publication date: 2008-02-01